Retinset

Retinset is a Spanish clinical-stage biotech spin-out from Medical Mix, focused on addressing the significant unmet need in early-stage diabetic retinopathy (DR). The company has developed a proprietary drug delivery platform that enables therapeutic agents to reach the retina via eye drops, a non-invasive alternative to current late-stage interventions. Its lead candidate, BSL01, has successfully completed a Phase I clinical trial and aims to stop and even reverse the progression of DR in its early stages. Retinset targets a global patient population of over 140 million people suffering from DR.

Patented formulation platform for ophthalmic drug delivery that enables therapeutic agents to effectively reach the retina via topical eye drops. Features eco-friendly formulations.

Current competitors focus on late-stage DR with invasive treatments (intravitreal injections, lasers). Retinset has a first-mover advantage in developing a pharmacological treatment for early-stage DR. Potential future competitors include other biotechs developing topical formulations or sustained-release implants for retinal delivery, but the space for early-stage intervention remains relatively open.